A Phase 1 Study to Evaluate MEDI4736 at Treatment for Advanced Malignant Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, or Colorectal Cancer
This Phase I study is designed to evaluate MEDI4736 in advanced cancer patients.
The primary objective is to determine the best dose of MEDI4736 to use when treating patients with metastatic or unresectable advanced solid tumors.
The study will enroll approximately 90 patients from at least 5 cancer centers in the US.
In addition to other conditions for enrollment, eligible patients have advanced malignant melanoma, renal cell carcinoma, non-small cell lung cancer, or colorectal cancer that has not responded to standard therapy and for which no standard therapy exists.
Patients who have a history of treatment with an anti-PD-1 agent/antibody, tuberculosis, hepatitis A, B, or C infection, symptomatic or untreated central nervous system disease or other severe medical conditions may not be eligible to enroll.